ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Comparative effectiveness of two alternative dosing strategies of pembrolizumab in metastatic non-small-cell lung cancer in a real-world setting.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPembrolizumab, a PD-1 immune checkpoint inhibitor, has become a standard first-line treatment for metastatic non-small cell lung cancer (mNSCLC), administered either as monotherapy or combined with platinum-based chemotherapy. Although current guidelines endorse a fixed dose of 200 mg every three weeks, initial clinical studies supported a weight-based dosing strategy (2 mg/Kg). The comparative effectiveness of these dosing strategies in real-world settings remains unclear.
methodsA multicenter, retrospective cohort study was conducted across three universitary hospitals to compare the effectiveness of two pembrolizumab dosing regimens as first line treatment in patients with mNSCLC. Patients were divided into two groups: the standard-dose group (STD, ≤ 2 mg/Kg) and high-dose group (HD, > 2 mg/Kg), both administered every 3 weeks. Primary endpoints were progression-free survival (PFS) and overall survival (OS). Kaplan-Meier and Cox regression analyses were used to compare outcomes between dosing groups.
resultsAmong 198 patients analyzed, baseline characteristics were similar between groups, except for a higher proportion of ECOG 0 in the HD group. Median PFS was 14.9 months in the STD group versus 8.3 months in the HD group, without statistical significance (HR 1.27, 95% CI 0.87-1.86, p = 0.215). Similarly, median OS was numerically longer in the STD group (27.7 months) compared to the HD group (17.3 months) (HR 1.39, 95% CI 0.97-2.03, p = 0.072). Rates of treatment discontinuation due to adverse events were similar between groups.
conclusionsIn this real-world cohort of mNSCLC patients, pembrolizumab administered at 2 mg/Kg every three weeks appears to provide similar progression free survival and overall survival outcomes compared to higher doses. These findings support the clinical effectiveness of lower pembrolizumab doses, aligning with prior pharmacokinetic and clinical studies indicating a lack of dose-response relationship for PD-1 inhibitors in mNSCLS, potentially optimizing treatment cost without compromising survival outcomes.
Indexed as
Identifiers
42387154What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.